Literature DB >> 31875504

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Catherine R Rowan1, Karen Boland1, Gavin C Harewood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31875504     DOI： 10.1056/NEJMc1915042

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects.

Authors:  Lei Gao; Qingmei Li; Hong Zhang; Min Wu; Min Fang; Lizhi Yang; Xiaojiao Li; Jingrui Liu; Cuiyun Li; Hong Chen; Xiaoxue Zhu; Yanhua Ding; Mingwei Zhou
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

2.  Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-κB.

Authors:  Ying Liu; Wenhua Wei; Shiwei Liang; Haicheng Fang; Jie Cao
Journal:  Ann Transl Med       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.